Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark‐2 study. Issue 9 (23rd January 2023)

• Record Type: Journal Article
• Authors: Cabasag, Citadel J.; Arnold, Melina; Rutherford, Mark; Ferlay, Jacques; Bardot, Aude; Morgan, Eileen; Butler, John; O'Connell, Dianne L.; Nelson, Gregg; Høgdall, Claus; Schnack, Tine; Gavin, Anna; Elwood, Mark; Hanna, Louise; Gourley, Charlie; De, Prithwish; Saint‐Jacques, Nathalie; Mørch, Lina Steinrud; Woods, Ryan R; Altman, Alon D.; Sykes, Peter; Cohen, Paul A.; McNally, Orla; Møller, Bjørn; Walsh, Paul; Morrison, David S.; Bray, Freddie; Soerjomataram, Isabelle
• Is Part Of: International journal of cancer. Volume 152:Issue 9(2023)
• Page Start: 1763
• Page End: 1777
• Publication Date: 2023-01-23
• Subjects: cancer surveillance -- epithelial ovarian cancer -- histological subtype -- net survival -- population‐based; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.34403
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract: The aim of the study is to provide a comprehensive assessment of incidence and survival trends of epithelial ovarian cancer (EOC) by histological subtype across seven high income countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom). Data on invasive EOC diagnosed in women aged 15 to 99 years during 1995 to 2014 were obtained from 20 cancer registries. Age standardized incidence rates and average annual percentage change were calculated by subtype for all ages and age groups (15‐64 and 65‐99 years). Net survival (NS) was estimated by subtype, age group and 5‐year period using Pohar‐Perme estimator. Our findings showed marked increase in serous carcinoma incidence was observed between 1995 and 2014 among women aged 65 to 99 years with average annual increase ranging between 2.2% and 5.8%. We documented a marked decrease in the incidence of adenocarcinoma "not otherwise specified" with estimates ranging between 4.4% and 7.4% in women aged 15 to 64 years and between 2.0% and 3.7% among the older age group. Improved survival, combining all EOC subtypes, was observed for all ages combined over the 20‐year study period in all countries with 5‐year NS absolute percent change ranging between 5.0 in Canada and 12.6 in Denmark. Several factors such as changes in guidelines and advancement in diagnostic tools may potentially influence the observed shift in histological subtypes and temporal trends. Progress in clinical management and treatment over the past decades potentially plays a role in the observed improvements in EOC survival. Abstract : What's new? Ovarian cancer remains the eighth leading cause of cancer death among women. Here, the authors assessed the incidence and survival trends of epithelial ovarian cancer from 1995 to 2014 in seven high‐income countries with universal access to healthcare: Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom. They found an increase in incidence of serous carcinoma among women age 65 and up, and a decrease in adenocarcinoma "not otherwise specified, " a trend which may reflect improvements in diagnostic pathology. While survival varied by age and by subtype, they observed an overall increase in survival among all groups.